What question did this study set out to answer?

To evaluate the in vitro synergistic antifungal efficacy of bacillomycin D combined with amphotericin B against pathogenic Candida species and assess toxicity in mammalian cells.

May 7, 2015FEMS Yeast Research

Synergistic fungicidal activity of the lipopeptide bacillomycin D with amphotericin B against pathogenic Candida species

View Full Paper

Ask AI

Bookmark

Authors

OTOlfa Tabbene DADi Grazia Antonio SAS. Azaiez

Discussion

Member takes

Overview

In vitro study demonstrates synergistic fungicidal activity of bacillomycin D and amphotericin B against Candida species, suggesting a low-toxicity topical alternative to conventional antifungals.

Key Points

To evaluate the in vitro synergistic antifungal efficacy of bacillomycin D combined with amphotericin B against pathogenic Candida species and assess toxicity in mammalian cells.
Determined minimum inhibitory concentrations and fractional inhibitory concentration indices for bacillomycin D alone and combined with amphotericin B against pathogenic Candida strains.
Conducted time-kill assays on Candida albicans ATCC 10231 cells and measured cytotoxicity in mammalian cells exposed to synergistic drug concentrations.
Bacillomycin D inhibited Candida species at 12.5 to 25 μg ml⁻¹ and acted synergistically with amphotericin B, producing fractional inhibitory concentration indices between 0.28 and 0.5.
Co-treatment with subinhibitory concentrations yielded a >2-log reduction in Candida albicans ATCC 10231 cell viability after 3 hours of incubation.
Synergistic drug dosages produced no observable cytotoxic effects against mammalian cells.

Cite This Study

Tabbene et al. (2015) studied this question.

synapsesocial.com/papers/6aa4e37df197b883c13d63aa https://doi.org/10.1093/femsyr/fov022

View Full Paper

Ask AI

Bookmark

May 7, 2015FEMS Yeast Research

Synergistic fungicidal activity of the lipopeptide bacillomycin D with amphotericin B against pathogenic Candida species

View Full Paper

Ask AI

Bookmark

Authors

OTOlfa Tabbene DADi Grazia Antonio SAS. Azaiez

Discussion

Member takes

Overview

In vitro study demonstrates synergistic fungicidal activity of bacillomycin D and amphotericin B against Candida species, suggesting a low-toxicity topical alternative to conventional antifungals.

Key Points

To evaluate the in vitro synergistic antifungal efficacy of bacillomycin D combined with amphotericin B against pathogenic Candida species and assess toxicity in mammalian cells.
Determined minimum inhibitory concentrations and fractional inhibitory concentration indices for bacillomycin D alone and combined with amphotericin B against pathogenic Candida strains.
Conducted time-kill assays on Candida albicans ATCC 10231 cells and measured cytotoxicity in mammalian cells exposed to synergistic drug concentrations.
Bacillomycin D inhibited Candida species at 12.5 to 25 μg ml⁻¹ and acted synergistically with amphotericin B, producing fractional inhibitory concentration indices between 0.28 and 0.5.
Co-treatment with subinhibitory concentrations yielded a >2-log reduction in Candida albicans ATCC 10231 cell viability after 3 hours of incubation.
Synergistic drug dosages produced no observable cytotoxic effects against mammalian cells.

Cite This Study

Tabbene et al. (2015) studied this question.

synapsesocial.com/papers/6aa4e37df197b883c13d63aa https://doi.org/10.1093/femsyr/fov022

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark